Anti–COVID-19 Drug Design by targeting a molecular scissor of Ubiquitin and ISG15.

UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances, describing the activity profiling and crystal structures of inhibitor bound SARS-CoV-2 PLpro:

Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design.
Wioletta Rut (1,*,†), Zongyang Lv (2,3,*), Mikolaj Zmudzinski (1), Stephanie Patchett (4), Digant Nayak (2,3), Scott J. Snipas (5), Farid El Oualid (6), Tony T. Huang (3,†), Miklos Bekes (7,†,‡), Marcin Drag (1,5,†), Shaun K. Olsen (2,3,†)

(1) Wroclaw University of Science and Technology, Poland. (2) Medical University of South Carolina, Charleston, USA. (3) University of Texas Health Science Center at San Antonio, San Antonio, USA. (4) New York University School of Medicine, New York, USA. (5) Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA. (6) UbiQ Bio B.V., Amsterdam, The Netherlands. (7) Independent Consultant. (*) These authors contributed equally to this work. (†) Corresponding author. (‡) Present address: Arvinas Inc., New Haven, USA.

Science Advances 2020, Vol. 6, no. 42, eabd4596. DOI: 10.1126/sciadv.abd4596